No Difference in Effectiveness of Treatment Simplification to Boosted or Unboosted Atazanavir Plus Lamivudine in Virologically Suppressed in HIV-1-infected Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Sep 21

PMID 30235244

Authors

Alicia Gutierrez-Valencia

Coral Garcia

Pompeyo Viciana

Yusnelkis Milanes-Guisado

Tamara Fernandez-Magdaleno

Nuria Espinosa

Juan Pasquau

Luis Fernando Lopez-Cortes

Affiliations

Soon will be listed here.

Abstract

Background: Simplification strategies of antiretroviral treatment represent effective tools for the reduction of drug-induced toxicity, resistance mutations in case of virological failure and costs.

Objectives: To assess the effectiveness of simplification to atazanavir/ritonavir (ATVrtv) or unboosted atazanavir (ATV400) plus lamivudine, and if low plasma or intracellular ATV Ctrough influence virological outcomes.

Methods: Ambispective observational study in patients with undetectable HIV-RNA who were switched to ATVrtv or ATV400 plus lamivudine once daily. Previous virological failures (VF) were allowed if the resistance tests showed major resistance mutation neither to ATV nor to lamivudine. VF was defined as two consecutive plasma HIV-RNA >200 copies/mL. Effectiveness was assessed by intention-to-treat and on-treatment analyses. Plasma and intracellular ATV Ctrough were measured by LC-MS/MS.

Result: A total of 246 patients were included. At week 48, the Kaplan-Meier estimation of efficacy within the ATVrtv and ATV400 groups were 85.9% [95% confidence interval, (CI95), 80.3-91.4%] versus 87.6% (CI95, 80.1-94.1%) by intention-to-treat analysis (p = 0.684), and 97.7% (CI95, 95.2-100%) versus 98.8% (CI95, 97.0-100%) by on-treatment analysis (p = 0.546), respectively. Plasma and intracellular Ctrough were significantly higher with ATVrtv than with ATV400 (geometric mean (GM), 318.3 vs. 605.9 ng/mL; p = 0.013) and (811.3 vs. 2659.2 ng/mL; p = 0.001), respectively. Only 14 patients had plasma Ctrough below the suggested effective concentration for ATV (150 ng/mL). No relationship between plasma or intracellular Ctrough and VF or blips were found.

Conclusion: Boosted or unboosted ATV plus lamivudine is effective and safe, and the lower plasma Ctrough observed with ATV400 do not compromise the effectiveness of these simplification regimens in long-term virologically suppressed HIV-1-infected patients.

References

Latini A, Fabbiani M, Borghi V, Sterrantino G, Giannetti A, Lorenzini P . Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis. 2016; 16(1):401. PMC: 4982404. DOI: 10.1186/s12879-016-1703-z. View

Lopez-Cortes L, Castano M, Lopez-Ruz M, Rios-Villegas M, Hernandez-Quero J, Merino D . Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens. PLoS One. 2016; 11(2):e0148924. PMC: 4752289. DOI: 10.1371/journal.pone.0148924. View

Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G . Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther. 2010; 15(7):993-1002. DOI: 10.3851/IMP1666. View

Calza L, Cafaggi M, Colangeli V, Borderi M, Barchi E, Lanzafame M . Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infect Dis (Lond). 2017; 50(5):352-360. DOI: 10.1080/23744235.2017.1410285. View

Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaut J . A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study.... N Engl J Med. 1998; 339(18):1269-76. DOI: 10.1056/NEJM199810293391802. View

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C . Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007; 44(11):1484-92. DOI: 10.1086/517497. View

Perez-Molina J, Rubio R, Rivero A, Pasquau J, Suarez-Lozano I, Riera M . Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority.... Lancet Infect Dis. 2015; 15(7):775-84. DOI: 10.1016/S1473-3099(15)00097-3. View

Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge M, Pierard D . HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis. 2012; 12:100. PMC: 3445837. DOI: 10.1186/1471-2334-12-100. View

Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C . Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit. 2011; 33(3):303-8. DOI: 10.1097/FTD.0b013e31821c2772. View

10.

Smith D, Jeganathan S, Ray J . Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2006; 7(1):34-8. DOI: 10.1310/0KX0-H9VH-99EE-5D0L. View

11.

Molto J, Santos J, Valle M, Miranda C, Miranda J, Blanco A . Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit. 2007; 29(5):648-51. DOI: 10.1097/FTD.0b013e31815704c1. View

12.

Carbone A, Galli L, Bigoloni A, Bossolasco S, Guffanti M, Maillard M . Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. J Int AIDS Soc. 2014; 17(4 Suppl 3):19811. PMC: 4225246. DOI: 10.7448/IAS.17.4.19811. View

13.

Llibre J, Cozzi-Lepri A, La Rosa J, Pedersen C, Ristola M, Losso M . Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. J Int AIDS Soc. 2014; 17(4 Suppl 3):19810. PMC: 4225315. DOI: 10.7448/IAS.17.4.19810. View

14.

Pulido F, Ribera E, Lagarde M, Perez-Valero I, Palacios R, Iribarren J . Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral.... Clin Infect Dis. 2017; 65(12):2112-2118. DOI: 10.1093/cid/cix734. View

15.

Colombo S, Buclin T, Cavassini M, Decosterd L, Telenti A, Biollaz J . Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006; 50(11):3801-8. PMC: 1635184. DOI: 10.1128/AAC.00098-06. View

16.

Squires K, Young B, DeJesus E, Bellos N, Murphy D, Zhao H . Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010; 24(13):2019-27. DOI: 10.1097/QAD.0b013e32833bee1b. View

17.

Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, DAvino A, Borghetti A . Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. J Antimicrob Chemother. 2015; 70(6):1843-9. DOI: 10.1093/jac/dkv037. View

18.

Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt E . Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr. 2005; 39(2):174-80. View

19.

Maggiolo F, Di Filippo E, Valenti D, Serna Ortega P, Callegaro A . NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe). J Acquir Immune Defic Syndr. 2016; 72(1):46-51. DOI: 10.1097/QAI.0000000000000966. View

20.

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, DEttorre G, Antinori A . Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017; 72(4):1163-1171. DOI: 10.1093/jac/dkw557. View